Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in In Vitro Models of Prostate Cancer Drug Resistance

Scientists reported the synthesis and biological characterization of a novel class of compounds designed through covalently linking enzalutamide and epichlorohydrin scaffolds-001 through various triazole based linkers.